An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Asthma

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion criteria:
Participants with a physician diagnosis of moderate to severe, uncontrolled asthma for >=12 months, based on the Global Initiative for Asthma (GINA) 2009 Guidelines and:
- Existing treatment with moderate or high-dose inhaled corticosteroid / long-acting beta-2 agonist
- Forced expiratory volume (FEV1) 40 to 80% of predicted normal
- Asthma Control Questionnaire, 5-question version (ACQ-5) score >=1.5
- Reversibility of at least 12% and 200 mL in forced expiratory volume (FEV1)
- Had experienced, within prior year: hospitalization, emergency or urgent care visit or systemic corticosteroid treatment for worsening asthma
Exclusion criteria:
- Participants <18 years
- Chronic obstructive pulmonary disease (COPD) or other lung diseases (eg, emphysema, idiopathic pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis) which impaired pulmonary function tests
- Chest X-ray within 12 months of screening visit or at screening visit with clinically significant findings of lung disease(s) other than asthma
- Current smoker or cessation of smoking within 6 months prior to Visit 1
- Previous smoker with a smoking history >10 pack-years
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Sites / Locations
- Investigational Site Number 840050
- Investigational Site Number 840041
- Investigational Site Number 840019
- Investigational Site Number 840029
- Investigational Site Number 840022
- Investigational Site Number 840013
- Investigational Site Number 840044
- Investigational Site Number 840007
- Investigational Site Number 840014
- Investigational Site Number 840036
- Investigational Site Number 840032
- Investigational Site Number 840040
- Investigational Site Number 840043
- Investigational Site Number 840006
- Investigational Site Number 840024
- Investigational Site Number 840027
- Investigational Site Number 840039
- Investigational Site Number 840048
- Investigational Site Number 840026
- Investigational Site Number 840053
- Investigational Site Number 840017
- Investigational Site Number 840030
- Investigational Site Number 840028
- Investigational Site Number 840052
- Investigational Site Number 840045
- Investigational Site Number 840046
- Investigational Site Number 840051
- Investigational Site Number 840018
- Investigational Site Number 840002
- Investigational Site Number 840003
- Investigational Site Number 840037
- Investigational Site Number 840004
- Investigational Site Number 840011
- Investigational Site Number 840016
- Investigational Site Number 840025
- Investigational Site Number 840015
- Investigational Site Number 840020
- Investigational Site Number 840001
- Investigational Site Number 840031
- Investigational Site Number 840034
- Investigational Site Number 840042
- Investigational Site Number 840010
- Investigational Site Number 840009
- Investigational Site Number 840021
- Investigational Site Number 840023
- Investigational Site Number 840005
- Investigational Site Number 840008
- Investigational Site Number 840035
- Investigational Site Number 840054
- Investigational Site Number 840033
- Investigational Site Number 032004
- Investigational Site Number 032003
- Investigational Site Number 032008
- Investigational Site Number 032010
- Investigational Site Number 032001
- Investigational Site Number 032002
- Investigational Site Number 032005
- Investigational Site Number 032006
- Investigational Site Number 032007
- Investigational Site Number 032012
- Investigational Site Number 032009
- Investigational Site Number 036004
- Investigational Site Number 036002
- Investigational Site Number 036005
- Investigational Site Number 036001
- Investigational Site Number 036008
- Investigational Site Number 036003
- Investigational Site Number 036009
- Investigational Site Number 036006
- Investigational Site Number 152007
- Investigational Site Number 152011
- Investigational Site Number 152001
- Investigational Site Number 152002
- Investigational Site Number 152014
- Investigational Site Number 152003
- Investigational Site Number 152005
- Investigational Site Number 152012
- Investigational Site Number 152013
- Investigational Site Number 152008
- Investigational Site Number 152006
- Investigational Site Number 250009
- Investigational Site Number 250004
- Investigational Site Number 250010
- Investigational Site Number 250006
- Investigational Site Number 250001
- Investigational Site Number 250002
- Investigational Site Number 250005
- Investigational Site Number 250007
- Investigational Site Number 250003
- Investigational Site Number 250008
- Investigational Site Number 250011
- Investigational Site Number 380010
- Investigational Site Number 380009
- Investigational Site Number 380004
- Investigational Site Number 380002
- Investigational Site Number 380008
- Investigational Site Number 380003
- Investigational Site Number 380007
- Investigational Site Number 380001
- Investigational Site Number 380005
- Investigational Site Number 380006
- Investigational Site Number 392009
- Investigational Site Number 392037
- Investigational Site Number 392002
- Investigational Site Number 392007
- Investigational Site Number 392012
- Investigational Site Number 392017
- Investigational Site Number 392021
- Investigational Site Number 392030
- Investigational Site Number 392004
- Investigational Site Number 392032
- Investigational Site Number 392013
- Investigational Site Number 392042
- Investigational Site Number 392026
- Investigational Site Number 392023
- Investigational Site Number 392001
- Investigational Site Number 392022
- Investigational Site Number 392025
- Investigational Site Number 392040
- Investigational Site Number 392044
- Investigational Site Number 392010
- Investigational Site Number 392036
- Investigational Site Number 392041
- Investigational Site Number 392020
- Investigational Site Number 392015
- Investigational Site Number 392005
- Investigational Site Number 392043
- Investigational Site Number 392019
- Investigational Site Number 392024
- Investigational Site Number 392011
- Investigational Site Number 392008
- Investigational Site Number 392034
- Investigational Site Number 392038
- Investigational Site Number 392028
- Investigational Site Number 392006
- Investigational Site Number 392003
- Investigational Site Number 392029
- Investigational Site Number 392018
- Investigational Site Number 392045
- Investigational Site Number 392014
- Investigational Site Number 392035
- Investigational Site Number 410002
- Investigational Site Number 410003
- Investigational Site Number 410004
- Investigational Site Number 410005
- Investigational Site Number 410001
- Investigational Site Number 484006
- Investigational Site Number 484005
- Investigational Site Number 484001
- Investigational Site Number 484004
- Investigational Site Number 484003
- Investigational Site Number 554001
- Investigational Site Number 554002
- Investigational Site Number 616006
- Investigational Site Number 616004
- Investigational Site Number 616003
- Investigational Site Number 616007
- Investigational Site Number 616001
- Investigational Site Number 616005
- Investigational Site Number 616008
- Investigational Site Number 643003
- Investigational Site Number 643002
- Investigational Site Number 643007
- Investigational Site Number 643012
- Investigational Site Number 643001
- Investigational Site Number 643006
- Investigational Site Number 643010
- Investigational Site Number 643011
- Investigational Site Number 643009
- Investigational Site Number 643008
- Investigational Site Number 710001
- Investigational Site Number 710002
- Investigational Site Number 724005
- Investigational Site Number 724002
- Investigational Site Number 724001
- Investigational Site Number 724004
- Investigational Site Number 724006
- Investigational Site Number 724003
- Investigational Site Number 724007
- Investigational Site Number 792011
- Investigational Site Number 792002
- Investigational Site Number 792008
- Investigational Site Number 792007
- Investigational Site Number 792001
- Investigational Site Number 792004
- Investigational Site Number 792003
- Investigational Site Number 792005
- Investigational Site Number 792013
- Investigational Site Number 792006
- Investigational Site Number 804016
- Investigational Site Number 804001
- Investigational Site Number 804004
- Investigational Site Number 804003
- Investigational Site Number 804008
- Investigational Site Number 804018
- Investigational Site Number 804020
- Investigational Site Number 804006
- Investigational Site Number 804002
- Investigational Site Number 804019
- Investigational Site Number 804015
- Investigational Site Number 804012
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Dupilumab 300 mg q2w
Dupilumab 200 mg q2w
Dupilumab 300 mg q4w
Dupilumab 200 mg q4w
Placebo q2w
2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.